CN116615268A - 在基因疗法中用于使用交变电场的方法和组合物 - Google Patents

在基因疗法中用于使用交变电场的方法和组合物 Download PDF

Info

Publication number
CN116615268A
CN116615268A CN202180086830.9A CN202180086830A CN116615268A CN 116615268 A CN116615268 A CN 116615268A CN 202180086830 A CN202180086830 A CN 202180086830A CN 116615268 A CN116615268 A CN 116615268A
Authority
CN
China
Prior art keywords
electric field
alternating electric
cells
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086830.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·沃洛申-塞拉
L·阿维格多
Y·珀拉特
H·玛姆布拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novokule Co ltd
Original Assignee
Novokule Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novokule Co ltd filed Critical Novokule Co ltd
Publication of CN116615268A publication Critical patent/CN116615268A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36002—Cancer treatment, e.g. tumour
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180086830.9A 2020-12-24 2021-12-22 在基因疗法中用于使用交变电场的方法和组合物 Pending CN116615268A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130449P 2020-12-24 2020-12-24
US63/130449 2020-12-24
PCT/IB2021/062198 WO2022137171A2 (en) 2020-12-24 2021-12-22 Methods and compositions for using alternating electric fields in gene therapy

Publications (1)

Publication Number Publication Date
CN116615268A true CN116615268A (zh) 2023-08-18

Family

ID=80121763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086830.9A Pending CN116615268A (zh) 2020-12-24 2021-12-22 在基因疗法中用于使用交变电场的方法和组合物

Country Status (5)

Country Link
US (1) US20220203088A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267236B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502295A (cg-RX-API-DMAC7.html)
CN (1) CN116615268A (cg-RX-API-DMAC7.html)
WO (1) WO2022137171A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7886853B2 (ja) * 2020-09-18 2026-07-08 ノボキュア ゲーエムベーハー コロナウイルスを処置するための方法及び組成物
JP2025520663A (ja) * 2022-06-21 2025-07-03 ノボキュア ゲーエムベーハー 交流電場とcrispr-casシステムを用いた症状および疾患の治療システムおよび方法
CN115845254B (zh) * 2022-11-23 2024-02-02 湖南安泰康成生物科技有限公司 小细胞肺癌治疗系统以及交变电场发生装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
WO1999011771A1 (en) * 1997-09-04 1999-03-11 Science Research Laboratory, Inc. Cell separation using electric fields
SE9704076D0 (sv) * 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US7016725B2 (en) 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
US8447395B2 (en) 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US20040092860A1 (en) * 2000-07-26 2004-05-13 Dev Nagendu B. Skin and muscle-targeted gene therapy by pulsed electrical field
WO2005115535A2 (en) 2004-04-23 2005-12-08 Novocure Ltd. Treating a tumor or the like with electric fields at different frequencies
CN102488967B (zh) * 2004-12-27 2016-03-30 诺沃库勒有限公司 利用电场从不同方向治疗肿瘤等
EP3143124B1 (en) * 2014-05-12 2025-01-22 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US20200308560A1 (en) * 2017-06-26 2020-10-01 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
KR102793500B1 (ko) * 2018-05-02 2025-04-14 그랜드 디케이드 디벨로프먼츠 리미티드 전기천공 시스템, 방법, 및 장치
KR102870236B1 (ko) * 2018-07-03 2025-10-14 에드윈 창 세포막 투과성을 향상시키기 위한 교류 전기장 사용
WO2020047387A1 (en) * 2018-08-31 2020-03-05 Thomas Jefferson University In vivo genetic engineering of antigen responsive cells
CN113164525B (zh) * 2018-10-23 2025-03-14 利兰·斯坦福青年大学托管委员会 在基于干细胞的疗法中使用交变电场预防和治疗畸胎瘤形成

Also Published As

Publication number Publication date
EP4267236A2 (en) 2023-11-01
EP4267236B1 (en) 2026-06-24
WO2022137171A2 (en) 2022-06-30
US20220203088A1 (en) 2022-06-30
JP2024502295A (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
US20230338443A1 (en) Expression of pten-long with oncolytic viruses
ES2786051T3 (es) Vector retroviral con casete de mini-promotor
US20220203088A1 (en) Methods And Compositions For Using Alternating Electric Fields In Gene Therapy
Kaur et al. Addressing the challenge: current and future directions in ovarian cancer therapy
US20200048716A1 (en) Using minivectors to treat ovarian cancer
US12385067B2 (en) Compositions and therapeutic methods of microRNA gene delivery
US20230257771A1 (en) Aav delivery system for lung cancer treatment
WO2017077275A1 (en) Phagemid vector
US20230383275A1 (en) Sgrna targeting aqp1 rna, and vector and use thereof
US20220040329A1 (en) Inducible expression cassette, and uses thereof
WO2016030501A1 (en) Synthetic alu-retrotransposon vectors for gene therapy
JP5486502B2 (ja) 癌治療用の多数の発現カセットを含む構造体
US20210147502A1 (en) Recombinant cancer therapeutic cytokine
Galanopoulos et al. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
Cusack et al. Introduction to cancer gene therapy
ES2640113T3 (es) Método para producir un vector viral para la transferencia génica
Dhakad et al. Review on Gene Therapy on Cancer
Kang et al. The piggyBac transposon is an integrating non‐viral gene transfer vector that enhances the efficiency of GDEPT
Alavi et al. Novel approaches and limitations in viral gene therapy of cancer diseases
Xu et al. Pancreatic cancer: gene therapy approaches and gene delivery systems
Chaudhary et al. Gene Drug Delivery for the Treatment of Cancer
WO2021168266A1 (en) Eradication of merkel cell polyomavirus
Mishra et al. Gene Therapy for Treatment of Pancreatic Cancer
WO2014050927A1 (ja) Va遺伝子破壊アデノウイルスベクターおよびそれを調製するための前駆体ベクター
Pradilla et al. Gene therapy for malignant brain tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination